STAA
BEARISH
$25.08
Live
STAAR Surgical Company · NASDAQ
Target $21.11
(-15.8%)
$15.59
52W Range
$30.81
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 20, 2026
Market cap
$1.24B
P/E
N/A
ROE
-21.7%
Profit margin
-33.6%
Debt/Equity
0.11
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
STAA exhibits severe fundamental weakness as evidenced by a critical Piotroski F-Score of 1/9, indicating a significant deterioration in financial health. While the company maintains a strong liquidity position (Current Ratio 4.55) and impressive gross margins (76.19%), it is unable to translate revenue growth into profitability, with a profit margin of -33.60%. The stock is currently trading at $25.08, which is a premium to the analyst target price of $21.11. Despite a favorable PEG ratio of 0.76, the lack of earnings stability and a bearish technical trend outweigh the growth potential.
Key Strengths
Strong gross margins of 76.19% indicating high product value
Excellent liquidity with a current ratio of 4.55
Very low leverage with a Debt/Equity ratio of 0.11
Consistent revenue growth of 18.10% YoY
Low PEG ratio (0.76) suggesting growth is undervalued relative to forward P/E
Key Risks
Severe financial health deterioration (Piotroski F-Score 1/9)
Negative profitability with a profit margin of -33.60%
Current price ($25.08) is significantly above the analyst target price ($21.11)
Highly volatile earnings track record with significant recent misses
Poor long-term price performance (5Y change of -78.7%)
AI Fair Value Estimate
Based on comprehensive analysis
$21.11
-15.8% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
26
Weak
40
55
20
15
0
AI Verdict
High Risk / Speculative
Key drivers: Piotroski F-Score, Negative Net Income, Revenue Growth, Liquidity
Confidence
90%
Value
40/100
Forward P/E of 32.57 is high given the current negative profit margins.
Positives
- PEG ratio of 0.76
Watchpoints
- Price/Sales of 5.19 is high for an unprofitable company
- Trading above analyst target
Future
55/100
Growth is present in top-line revenue but absent in bottom-line earnings.
Positives
- 18.10% YoY revenue growth
- Strong gross margins
Watchpoints
- Inconsistent EPS progression
- Failure to scale revenue into net profit
Past
20/100
Long-term trend is overwhelmingly bearish despite short-term bounces.
Positives
- Recent 1Y recovery (+48.5%)
Watchpoints
- Devastating 5Y return of -78.7%
- Consistent long-term value destruction
Health
15/100
While solvent (low debt), the operational health is critical (Piotroski 1/9).
Positives
- Low Debt/Equity
- High Current Ratio
Watchpoints
- Piotroski F-Score 1/9
- Negative ROE and ROA
Dividend
0/100
Company is in a growth/loss phase and does not return capital.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$25.08
Analyst Target
$21.11
Upside/Downside
-15.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for STAA and closest competitors.
Updated 2026-04-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
STAA
STAAR Surgical Company
Primary
|
-78.7% | -63.2% | +48.5% | +0.2% | +35.0% | -5.1% |
|
PHAR
Pharming Group N.V.
Peer
|
+33.8% | +54.0% | +114.2% | +20.5% | +11.9% | +2.1% |
|
NNNN
Anbio Biotechnology
Peer
|
+399.8% | +399.8% | +349.9% | +2.7% | +32.2% | +5.4% |
|
MRVI
Maravai LifeSciences Holdings, Inc.
Peer
|
-91.0% | -76.8% | +85.3% | +1.6% | +4.1% | +13.5% |
|
BLFS
BioLife Solutions, Inc.
Peer
|
-40.8% | -0.5% | -10.7% | +10.1% | -2.1% | +1.8% |
STA
STAAR Surgical Company
Primary
5Y
-78.7%
3Y
-63.2%
1Y
+48.5%
6M
+0.2%
1M
+35.0%
1W
-5.1%
PHA
Pharming Group N.V.
Peer
5Y
+33.8%
3Y
+54.0%
1Y
+114.2%
6M
+20.5%
1M
+11.9%
1W
+2.1%
NNN
Anbio Biotechnology
Peer
5Y
+399.8%
3Y
+399.8%
1Y
+349.9%
6M
+2.7%
1M
+32.2%
1W
+5.4%
MRV
Maravai LifeSciences Holdings, Inc.
Peer
5Y
-91.0%
3Y
-76.8%
1Y
+85.3%
6M
+1.6%
1M
+4.1%
1W
+13.5%
BLF
BioLife Solutions, Inc.
Peer
5Y
-40.8%
3Y
-0.5%
1Y
-10.7%
6M
+10.1%
1M
-2.1%
1W
+1.8%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
32.57
PEG Ratio
0.76
P/B Ratio
3.6
P/S Ratio
5.19
EV/Revenue
4.56
EV/EBITDA
-29.2
Market Cap
$1.24B
Profitability
Profit margins and return metrics
Profit Margin
-33.6%
Operating Margin
-18.87%
Gross Margin
76.19%
ROE
-21.7%
ROA
-5.95%
Growth
Revenue and earnings growth rates
Revenue Growth
+18.1%
Earnings Growth
N/A
Q/Q Revenue Growth
+18.08%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.11
Low debt
Current Ratio
4.55
Strong
Quick Ratio
3.53
Excellent
Cash/Share
$3.79
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
75.7%
Op. Margin
-18.9%
Net Margin
-31.7%
Total Assets
$0.5B
Liabilities
$0.1B
Equity
$0.3B
Debt/Equity
0.31x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
143%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-06
$N/A
2026-03-03
$0.01
-95.2% surprise
2025-11-05
$0.18
+47.3% surprise
2025-08-06
$-0.13
+77.0% surprise
Healthcare Sector Comparison
Comparing STAA against 470 companies in the Healthcare sector
(26 bullish, 143 neutral, 301 bearish)
Return on Equity (ROE)
-21.7%
This Stock
vs
-97.91%
Sector Avg
-77.8%
(Below Avg)
Profit Margin
-33.6%
This Stock
vs
-16.16%
Sector Avg
+107.9%
(Superior)
Debt to Equity
0.11
This Stock
vs
3.0
Sector Avg
-96.3%
(Less Debt)
Revenue Growth
18.1%
This Stock
vs
142.9%
Sector Avg
-87.3%
(Slower)
Current Ratio
4.55
This Stock
vs
4.65
Sector Avg
-2.2%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
STAA
STAAR Surgical Company
|
BEARISH | $1.24B | - | -21.7% | -33.6% | $25.08 | |
|
PHAR
Pharming Group N.V.
|
NEUTRAL | $1.22B | 433.25 | 1.0% | 0.8% | $17.33 | Compare |
|
NNNN
Anbio Biotechnology
|
BEARISH | $1.27B | 192.27 | 27.0% | 74.1% | $28.84 | Compare |
|
MRVI
Maravai LifeSciences Holdings, Inc.
|
NEUTRAL | $1.21B | - | -48.6% | -70.4% | $3.28 | Compare |
|
BLFS
BioLife Solutions, Inc.
|
NEUTRAL | $1.2B | - | -5.2% | -3.2% | $24.87 | Compare |
STAA
STAAR Surgical Company
BEARISH
Mkt Cap
$1.2B
P/E
-
ROE
-21.7%
Price
$25.08
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-13 | BROADWOOD PARTNERS, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | 670,213 | $12,266,545 |
| 2026-03-13 | MICHNA MAGDA | Officer | Stock Award | 23,773 | - |
| 2026-03-13 | FOUST WARREN | Chief Executive Officer | Stock Award | 37,500 | - |
| 2026-01-12 | JIANG WEI | Director | Stock Award | 20,967 | - |
| 2026-01-09 | BROADWOOD PARTNERS, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | 27,485 | $606,138 |
| 2026-01-08 | BROADWOOD PARTNERS, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | 406,653 | $8,817,664 |
| 2025-11-21 | BROADWOOD PARTNERS, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | 1,500,000 | $41,060,317 |
| 2025-11-12 | JIANG WEI | Director | Stock Award | 20,967 | - |
BROADWOOD PARTNERS, L.P.
Beneficial Owner of more than 10% of a Class of Security
2026-03-13
670,213 shares
·
$12,266,545
MICHNA MAGDA
Officer
2026-03-13
23,773 shares
FOUST WARREN
Chief Executive Officer
2026-03-13
37,500 shares
JIANG WEI
Director
2026-01-12
20,967 shares
BROADWOOD PARTNERS, L.P.
Beneficial Owner of more than 10% of a Class of Security
2026-01-09
27,485 shares
·
$606,138
BROADWOOD PARTNERS, L.P.
Beneficial Owner of more than 10% of a Class of Security
2026-01-08
406,653 shares
·
$8,817,664
BROADWOOD PARTNERS, L.P.
Beneficial Owner of more than 10% of a Class of Security
2025-11-21
1,500,000 shares
·
$41,060,317
JIANG WEI
Director
2025-11-12
20,967 shares
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
8-K
8-K
10-K
8-K
8-K
8-K
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
HOLD
9 analysts
Wedbush
2026-04-09
Neutral
Neutral
Canaccord Genuity
2026-04-09
Hold
Buy
Wells Fargo
2026-03-05
Equal-Weight
Equal-Weight
Stifel
2026-03-04
Hold
Hold
Stifel
2026-02-09
Hold
Hold
Wedbush
2026-02-03
Neutral
Jefferies
2026-01-28
Buy
Buy
Canaccord Genuity
2026-01-16
Hold
Hold
Wells Fargo
2025-12-10
Equal-Weight
Equal-Weight
Canaccord Genuity
2025-12-10
Hold
Hold
Past News Coverage
Recent headlines mentioning STAA from our newsroom.
Newest → oldest
No matching news yet.